Adverse Events Associated With CO-1686

Special Reports, NSCLC (Issue 3), Volume 3, Issue 1

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer (NSCLC).

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with the novel EGFR inhibitor CO-1686 for patients with non-small cell lung cancer (NSCLC).

View more on other next-generation therapies for NSCLC > >